ArticleThe Lancet regional health. Europe2025
5-Year conditional relative survival of adolescents and young adults with solid malignancies in the Netherlands: a population-based cohort study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing number of adolescent and young adult (AYA) cancer survivors highlights the importance of their reintegration into society. However, years after recovery, cancer survivors still need to disclose their cancer history when applying for insurance. Right to be forgotten (RTBF) laws aim to protect cancer survivors from financial discrimination by shortening the required disclosure period. The required period for a disease to be forgotten varies between countries up to ten years in the Netherlands. Currently, questions arise about whether existing RTBF laws disadvantage AYAs by grouping them with older patients. This observational study examined the long-term conditional relative survival (CRS) of AYA solid malignancy survivors to inform potential adjustments to RTBF laws. Methods: Data of all invasive solid malignancies diagnosed within the AYA population between 1998 and 2021 were obtained from the Netherlands Cancer Registry (NCR). The five-year CRS was calculated annually up to ten years post-diagnosis, using a hybrid analysis approach for the entire AYA solid malignancy cohort, and stratified by sex, age, and cancer type. Findings: The entire AYA solid malignancy survivor cohort (n = 71,973) reached the threshold of minimal excess mortality (CRS > 95%) four years post-diagnosis. For AYA survivors of germ cell and trophoblastic tumors (ovarian and testis), malignant melanoma, thyroid carcinoma, skin carcinoma, and neuroendocrine tumors (NET), the excess mortality was minimal (CRS > 95%) since diagnosis. Most other cancer types reached the 95% threshold within five or ten years post-diagnosis. Interpretation: These results can serve as a basis for the reappraisal of current RTBF regulations for AYA solid malignancy survivors in the Netherlands, which can have important implications for other European countries with RTBF policies. Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.